Conexeu Sciences Inc.

NASDAQ:CNXUHealthcare · Biotechnology

Mkt Cap$95.58M

Float14.71M

Shares O/S30.83M

Inst Own0.1%

SI1.4%

Dilution

-6.06%$3.10

AH Close$3.31+6.77%vs close

Mkt Cap$95.58M

Float14.71M

O/S30.83M

Inst Own0.1%

SI1.4%

Dilution

NASDAQ:CNXU$3.10-6.06%

MCap$95.58M

Float14.71M

O/S30.83M

SI1.4%

Inst Own0.1%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$95.58M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership0.09%

based on 30.83M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateMay 21, 2026

Shares Outstanding30.83M

Float14.71M

Company Overview

Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.

Leadership

Brian K. Pilcher

Chief Medical Officer

David R. Bogart

Founder & Director

Claudia Chavez-Munoz

Founder & Chief Scientific Officer

Stephen D. Inouye

CFO, Corporate Secretary & Treasurer

Employees

Country

Sector

Healthcare

Website

www.conexeu.com

Analyst Coverage

No analyst coverage for this companyNo ratings, price targets, or covering firms on file.

Insider Trading

Insider	Title	Type	Shares	Value	Date
Purcell Lynn Sebastian	Director	Purchase	166.7K	--	Oct 15, 2026
Purcell Lynn Sebastian	Director	Purchase	166.7K	$500.0K	Oct 15, 2026
Bogart David Robert	Chief Commercial Officer	Option Exercise	750.0K	$750	Sep 25, 2026
Bogart David Robert	Chief Commercial Officer	Option Exercise	750.0K	--	Sep 25, 2026
Sharpe Jeffrey Nathan	Director	Option Exercise	500.0K	$500	Sep 14, 2026
Sharpe Jeffrey Nathan	Director	Option Exercise	500.0K	--	Sep 14, 2026

Shareholders

0.1%

Institutional

(9)

20.1%

Insiderⓘ

(9)

18.9%

5%+ Owners

(2)

60.9%

Unattributed (incl. retail)ⓘ

Institutional0.1%

Insider20.1%

5%+ Beneficial18.9%

Unattributed (incl. retail)60.9%

Top Shareholders

Name	Shares	%	Source
Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund · may incl. warrants· filed Sep 2026	4.3M	14.0%	13G
Bogart David Robert Chief Commercial Officer, Director	1.8M	5.9%	FORM 4
Jeffrey Sharpe · may incl. warrants· filed Sep 2026	1.5M	4.9%	13D
OnePointTwo Capital Ventures II LLC 10% Owner	1.5M	4.8%	FORM 4
OnePointTwo Capital Ventures LLC 10% Owner	1.0M	3.4%	FORM 4
Wright Michael G. 10% Owner	750.0K	2.4%	FORM 4
Chavez-Munoz Claudia Itze Chief Science Officer	444.1K	1.4%	FORM 4
Lorenc Zbigniew Paul Director	433.3K	1.4%	FORM 4
Harrison Miles David President and CEO, Director	87.9K	0.3%	FORM 4
Pilcher Brian Keith Chief Medical Officer	87.9K	0.3%	FORM 4